# US 2016/0355496 A1 · Chromene derivatives and their analogs as wnt pathway antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355496 A1
- Document ID: US20160355496A1
- Status: Published application
- Kind: A1
- Application number: 15/158,733
- Filed: 2016-05-19
- Published: 2016-12-08
- Earliest claimed: 2010-11-12
- Assignees: Deutsches Krebsforschungszentrum; Ruprecht-Karls-UniversitäT Heidelberg
- Applicants: Deutsches Krebsforschungszentrum; Ruprecht-Karls-Universität Heidelberg
- Inventors: Michael BOUTROS; Rajendra-Prasad MASKEY; Corinna KOCH; Florian FUCHS; Sandra STEINBRINK; Daniel GILBERT
- Web page: https://patentgrep.com/patent/US20160355496A1

## CPC

- C07D 311/92: Naphthopyrans; Hydrogenated naphthopyrans
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 311/04: Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D 311/96: spiro-condensed with carbocyclic rings or ring systems
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 491/04: Ortho-condensed systems
- C07D 491/052: the oxygen-containing ring being six-membered
- C07D 493/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

## Claims

### Claim 1

A compound of formula (Ic)
wherein
X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different;
Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N;
R1; R2; R3; R4 and R5 are selected from H, OH; halogen; CN; C1-C6 alkyl; C2-C6 alkenyl; C2-C6 alkinyl; C3-C7 aryl; C3-C7 heteroaryl; C4-C15 aralkyl; C4-C15 heteroarylalkyl; C(O)R1a; C(O)OR1a; C(O)N(R1aR1b); N(R1a)S(O)2OR1b; N(R1aR1b); N(R1a)S(O)2N(R1bR1c); N(R1a)C(O)R1b; N(R1a)S(O)2R1b; N(R1a)S(O)R1b; N(R1a)C(O)N(R1bR1c); N(R1a)C(O)OR1b; SR1a; S(O)2OR1a; S(O)2N(R1aR1b); S(O)N(R1aR1b); S(O)2R1a; S(O)R1a; OR1a; OC(O)R1a; and OC(O)N(R1aR1b); and wherein alkyl; alkenyl, alkinyl, aryl; heteroaryl; aralkyl; and heteroarylalkyl are/is optionally substituted by one or more groups R10 which are same or different; optionally two adjacent substituents R1; R2; R3; R4 and R5 form together a 5- to 7-membered heterocyclic ring optionally substituted by one or more groups R10 which may be same or different;
and wherein at least 3 of the group of R1; R2; R3; R4; and R5 are not H;
R1a; R1b; and R1c are independently from each other selected from H; C1-C6 alkyl; C3-C7 cycloalkyl; C3-C7 heterocyclyl; C2-C6 alkenyl; C2-C6 alkinyl; C3-C7 aryl; C3-C7 heteroaryl; C4-C16 aralkyl; and C4-C15 heteroarylalkyl; wherein alkyl; cycloalkyl; heterocyclyl; alkenyl; alkinyl; aryl; heteroaryl; aralkyl; and heteroarylalkyl are/is optionally substituted with one or more R10 which are same or different;
R10 is selected from halogen; CN; OH, C1-C6 alkyl; OR10a; C(O)R10a; C(O)OR10a; C(O)N(R10aR10b); N(R10aR10b); OC(O)R10a; N(R10a)C(O)R10b; S(O)2N(R10aR10b); S(O)N(R10aR10b); S(O)2R10a; S(O)R10a; S(O)2OR10a; N(R10a)S(O)2N(R10bR10c); SR10a; N(R10a)S(O)2R10b; N(R10a)S(O)R10b; N(R10a)C(O)N(R10bR10c); and OC(O)N(R10aR10b); wherein C1-C6 alkyl is optionally substituted with one or more halogen which are same or different;
R10a; R10b and R10c are independently from each other selected from H; and C1-C6 alkyl; wherein C1-C6 alkyl is optionally substituted with one or more halogen which are same or different;
R6 is selected from CN; C(O)R6a; C(O)OR6a; C(O)N(R6aR6b); C(NR6a)N(R6bR6c); CR6aNOR6b; SR6a; S(O)R6a; S(O)2R6a; S(O)2OR6a; S(O)2N(R6aR6b); and S(O)N(R6aR6b);
R6a; R6b; and R6c are independently from each other selected from H; C1-C6 alkyl; C3-C7 cycloalkyl; C3-C7 heterocyclyl; C2-C6 alkenyl; C2-C6 alkinyl; C3-C7 aryl; C3-C7 heteroaryl; C4-C15 aralkyl; and C4-C15 heteroarylalkyl which are optionally substituted with one or more R11, which are the same or different;
R11 is selected from halogen; CN; OH; C1-C6 alkyl; OR11a; C(O)R11a; C(O)OR11a; C(O)N(R11aR11b); N(R11aR11b); OC(O)R11a; N(R11a)C(O)R11b; SR11a; S(O)R11a; S(O)2R11a; S(O)2OR11a; S(O)2N(R11aR11b); S(O)N(R11aR11b); N(R11a)S(O)2N(R11bR11c); N(R11a)S(O)2R11b; N(R11a)S(O)R11b; N(R11a)C(O)N(R11bR11c); and OC(O)N(R11aR11b); wherein C1-C6 alkyl is optionally substituted with one or more R18 which are the same or different;
R18 is selected from halogen, CN, OH; OR11a; C(O)R11a; C(O)OR11a; C(O)N(R11aR11b); N(R11aR11b); OC(O)R11a; N(R11a)C(O)R11b; SR11a; S(O)R11a; S(O)2R11a; S(O)2OR11a; S(O)2N(R11aR11b); S(O)N(R11aR11b); N(R11a)S(O)2N(R11bR11c); N(R11a)S(O)2R11b; N(R11a)S(O)R11b; N(R11a)C(O)N(R11bR11c); and OC(O)N(R11aR11b);
R11a; R11b; and R11c are independently from each other selected from H; and C1-C6 alkyl; wherein C1-C6 alkyl is optionally substituted with one or more halogen which are the same or different;
R7 is selected from H; OH; OR7a; OC(O)R7a; OC(O)N(R7aR7b); N(R7aR7b); N(R7a)C(O)R7b; N(R7a)C(O)N(R7bR7c); N(R7a)C(O)OR7b; N(R7a)S(O)2OR7b; N(R7a)S(O)R7b; N(R7a)S(O)2R7b; N(R7a)S(O)2N(R7bR7c);
R7a; R7b; and R7c are independently from each other selected from H; C1-C6 alkyl; C3-C7 cycloalkyl; C3-C7 heterocyclyl; C2-C6 alkenyl; C2-C6 alkinyl; C3-C7 aryl; C3-C7 heteroaryl; C4-C15 aralkyl; and C4-C15 heteroarylalkyl wherein alkyl; cycloalkyl; heterocyclyl; alkenyl; alkinyl; aryl; heteroaryl; aralkyl; heteroarylalkyl are optionally substituted with one or more R12, which are same or different;
R12 is selected from halogen; CN; OH; C1-C6 alkyl; OR12a; C(O)R12a; C(O)OR12a; C(O)N(R12aR12b); N(R12aR12b); OC(O)R12a; N(R12a)C(O)R12b; S(O)2N(R12aR12b); S(O)N(R12aR12b); S(O)2R12a; S(O)R12a; S(O)2OR12a; N(R12a)S(O)2N(R12bR12c); SR12a; N(R12a)S(O)2R12b; N(R12a)S(O)R12b; N(R12a)C(O)N(R12bR12c); N(R12a)C(O)OR12b; OC(O)N(R12aR12b); and S(O)2N(R11a)C(O)N(R11bR11c); wherein C1-C6 alkyl is optionally substituted with one or more halogen which are same or different;
R12a; R12b and R12c are independently from each other selected from H; and C1-C6 alkyl; wherein C1-C6 alkyl is optionally substituted with one or more halogen which are same or different;
R8 is selected from H; OH; CN, halogen, C1-C6 alkyl; C3-C7 cycloalkyl; C3-C7 heterocyclyl; C2-C6 alkenyl; C2-C6 alkinyl; C3-C7 aryl; C3-C7 heteroaryl; C4-C15 aralkyl; C4-C15 heteroarylalkyl; C(O)R8a; C(O)OR8a; C(O)N(R8aR8b); C(NR8a)N(R8bR8c); C(R8a)N(R8b); OR8a; OC(O)R8a; OC(O)N(R8aR8b); SR8a; S(O)R8a; S(O)2R8a; S(O)2OR8a; S(O)2N(R8aR8b); S(O)N(R8aR8b); S(O)2N(R8a)C(O)N(R8bR8c); N(R8a)S(O)2N(R8bR8c); N(R8a)S(O)2R8b; N(R8a)S(O)R8b; N(R8a)S(O)2OR8b; N(R8aR8b); N(R8a)C(O)R8b; N(R8a)C(O)N(R8bR8c); and N(R8a)C(S)N(R8bR8c); wherein alkyl; cycloalkyl; heterocyclyl; alkenyl; alkinyl; aryl; heteroaryl; aralkyl; and heteroarylalkyl are/is optionally substituted by one or more R16, which are same or different;
R8a and R8b; and R8c are independently from each other selected from H; C1-C6 alkyl; C3-C7 cycloalkyl; C3-C7 heterocyclyl; C2-C6 alkenyl; C2-C6 alkinyl; C3-C7 aryl; C3-C7 heteroaryl; C4-C15 aralkyl; and C4-C15 heteroarylalkyl which are optionally substituted with one or more R16, which are same or different;
R16 is selected from halogen; CN; OH; C1-C6 alkyl; OR16a; C(O)R16a; C(O)OR16a, C(O)N(R16aR16b); N(R16aR16b); OC(O)R16a; N(R16a)C(O)R16b; S(O)2N(R16aR16b); S(O)N(R16aR16b); S(O)2R16a; S(O)R16a; S(O)2OR16a; N(R16a)S(O)2N(R16bR16c); SR16a; N(R16a)S(O)2R16b; N(R16a)S(O)R16b; N(R16a)C(O)N(R16bR16c); and OC(O)N(R16aR16b); wherein C1-C6 alkyl is optionally substituted with one or more halogen which are same or different;
R16a and R16b and R16c are independently from each other selected from H; and C1-C6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen which are the same or different;
R9 is selected from H; OH; halogen; CN; C1-C6 alkyl; C3-C7 cycloalkyl; C3-C7 heterocyclyl; C2-C6 alkenyl; C2-C6 alkinyl; C3-C7 aryl; C3-C7 heteroaryl; C4-C15 aralkyl; C4-C15 heteroarylalkyl; OR9a; C(O)R9a; C(O)OR9a; C(O)N(R9aR9b); S(O)2N(R9aR9b); S(O)N(R9aR9b); S(O)2R9a; S(O)R9a; S(O)2OR9a; S(O)2N(R9a)C(O)N(R9bR9c); N(R9a)S(O)2N(R9bR9c); SR9a; OC(O)R9a; N(R9a)C(O)R9b; N(R9a)S(O)2R9b; N(R9a)S(O)R9b; N(R9a)C(O)N(R9bR9c); N(R9a)C(S)N(R9bR9c); OC(O)N(R9aR9b); C(NR9a)N(R9bR9c); N(R9a)S(O)2OR9b; N(R9aR9b); and C(R9a)NR9b; wherein alkyl; cycloalkyl; heterocyclyl; alkenyl; alkinyl; aryl; heteroaryl; aralkyl; and heteroarylalkyl are optionally substituted by one or more R13, which are same or different;
R9a; R9b; and R9c are independently from each other selected from H; C1-C6 alkyl; C3-C7 cycloalkyl; C3-C7 heterocyclyl; C2-C6 alkenyl; C2-C6 alkinyl C3-C7 aryl; C3-C7 heteroaryl; C4-C15 aralkyl; and C4-C15 heteroarylalkyl which are optionally substituted with one or more R13, which are same or different;
R13 is selected from halogen; CN; OH; C1-C6 alkyl; OR13a; C(O)R13a; C(O)OR13a; C(O)N(R13aR13b); N(R13aR13b); OC(O)R13a; N(R13a)C(O)R13b; S(O)2N(R13aR13b); S(O)N(R13aR13b), S(O)2R13a; S(O)2OR13a; S(O)R13a; N(R13a)S(O)2N(R13bR13c), SR13a; N(R13a)S(O)2R13b; N(R13a)S(O)R13b; N(R13a)C(O)N(R13bR13c); and OC(O)N(R13aR13b); wherein C1-C6 alkyl is optionally substituted with one or more halogen which are same or different;
R13a; R13b and R13c are independently from each other selected from H; and C1-C6 alkyl; wherein C1-C6 alkyl is optionally substituted with one or more halogen which are same or different;
and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein at least one substituent R9 is not H; and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein at least 1 member of the group X3, X4, Y1, Y2, Y3 and Y4 is N; and pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1; R4; and R5 are independently from each other selected from H; NH2; NHCH3; CH2OH; CH2OCH3; CH2NH2; CH2NHCH3; OH; OCH3; Br; F; and Cl; and R2 and R3 are independently from each other selected from H; NH2; NHCH3; CH2OH; CH2OCH3; CH2NH2; CH2NHCH3; OH; OCH3; Br; F; and Cl; or R2 and R3 are forming together OCH2O; and pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R8 is selected from H; OH; OR8a; NH2; NHR8a; N(R8aR8b); CH2OH; CH2OR16a; CH2NH2; CH2NHR16a; CH2N(R16aR16b); C(O)NH2; C(O)NHR8a; C(O)N(R8aR8b); C(O)OH; and C(O)OR8a;
R8a and R8b are independently from each other selected from C1-C6 alkyl which is optionally substituted with one or more halogen which are the same or different; OH, OR16a, NH2; NHR16a, NR16aR16;
R16a and R16b are independently from each other selected from C1-C6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen which are the same or different;
and R9 is selected H; OH; OR9a; NH2; NHR9a; N(R9aR9b); CH2OH; CH2OR13a; CH2NH2; CH2NHR13a; CH2N(R13aR13b); C(O)NH2; C(O)NHR9a; C(O)N(R9aR9b); C(O)OH; and C(O)OR9a;
R9a and R9b are independently from each other selected from C1-C6 alkyl which is optionally substituted with one or more halogen which are the same or different; OH, OR13a, NH2; NHR13a, NR13aR13b;
R13a and R13b are independently from each other selected from C1-C6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen which are the same or different;
and pharmaceutically acceptable salts thereof.

### Claim at position 6

-7. (canceled)

### Claim 8 (depends on 1)

The compound of claim 1, wherein said compound is a modulator of the Wnt signalling pathway.

### Claim 9 (depends on 1)

A method for the treatment of a disorder or disease associated with an aberrant activation of Wnt signalling in a mammal, said method comprising administering to said mammal a compound of claim 1.

### Claim 10 (depends on 9)

The method of claim 9, wherein the Wnt associated disorder or disease is a cell proliferative disorder, rheumatoid arthritis, increased bone density, aging or age-related disorders and/or diseases or Dupuytren disease (superficial fibromatosis).

### Claim 11 (depends on 10)

The method of claim 10, wherein the cell proliferation disorder is cancer or a proliferative skin disorder.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer is member of the group multiple myeloma, colon cancer, breast cancer, gastritic cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, bladder cancer, liver cancer, uterine cancer, kidney cancer, leukaemia, gliomas, basal cell carcinoma, rhabdomyosarcoma, mesothelioma, osteosarcoma, medulloblastomas and other primary CNS malignant neuroectodermal tumors.

### Claim 13 (depends on 1)

A pharmaceutical composition containing a compound of claim 1 in a pharmaceutical carrier.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13 in a kit.

### Claim 15 (depends on 1)

Method for the preparation of a medicament comprising the steps of: a) preparing at least one compound according to claim 1; and b) formulating a medicament containing at least said compound.

### Claim 16 (depends on 1)

A method of treating a mammal by modulation of the Wnt signalling pathway comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1.
